Labopharm Once-Daily Tramadol Is “Approvable”
This article was originally published in The Pink Sheet Daily
The Canadian firm may still have an opportunity to reach its end-of-2006 launch goal for the opioid analgesic.
You may also be interested in...
Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.
The company expects the analgesic to launch early in 2006, but continues negotiations over a marketing partnership.
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.